|
Associate Professor Sherene Loi is a medical oncologist specialised in the treatment of breast cancer and head of the Translational Breast Cancer Genomics laboratory at the Peter MacCallum Cancer Centre, Melbourne, Australia. She completed her medical oncology training in Melbourne, Australia in 2004 and then completed her PhD and 4 years of post-doctoral experience with Drs Christos Sotiriou and Martine Piccart in Brussels, Belgium. There she gained significant experience in the use of genomic technologies, drug development, clinical trial conduct and design. The aims of her lab are to understand the drivers and predictors of prognosis in breast cancer using high-throughput genomic technologies as well as using in vitro and in vivo preclinical models. Ultimately, the aim of her lab is to translate such findings into therapeutic approaches for breast cancer patients. Recently, she has developed a keen interest in immunotherapeutic approaches, as she was first to report on the positive prognostic value of tumor infiltrating lymphocytes in triple negative and HER2-positive breast cancer. Further preclinical work has supported the concept that immune approaches could be beneficial in these breast cancer subtypes. She also plays a role in many breast cancer clinical trials that evaluate targeted approaches as well as immunotherapies.
|
